Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib

被引：0
|
作者：
Yuko Oya
Tatsuya Yoshida
Kazuhiro Asada
Tetsuya Oguri
Naoki Inui
Sayako Morikawa
Kentaro Ito
Tomoki Kimura
Eiji Kunii
Takashi Matsui
Akihito Kubo
Tatsuo Kato
Takashi Abe
Takeshi Tsuda
Toyoaki Hida
机构：
[1] Aichi Cancer Center Hospital,Department of Thoracic Oncology
[2] National Cancer Center Hospital,Current Address: Department of Thoracic Oncology
[3] Shizuoka General Hospital,Department of Respiratory Medicine
[4] Nagoya City University,Department of Respiratory Medicine, Allergy and Clinical Immunology
[5] Hamamatsu University School of Medicine,Second Division, Department of Internal Medicine
[6] Fujita Health University School of Medicine,Department of Respiratory Medicine
[7] Matsusaka Municipal Hospital,Respiratory Center
[8] Tosei General Hospital,Department of Respiratory Medicine and Allergy
[9] Nagoya City West Medical Center,Department of Respiratory Medicine
[10] Seirei Mikatahara General Hospital,Department of Respiratory Medicine
[11] Aichi Medical University School of Medicine,Division of Respiratory Medicine and Allergology
[12] National Hospital Organization Nagara Medical Center,Department of Respiratory Medicine
[13] Ogaki Municipal Hospital,Department of Respiratory Medicine
[14] Toyama Prefectural Central Hospital,Department of Respiratory Medicine
来源：
BMC Cancer | / 21卷
关键词：
Epidermal growth factor receptor (EGFR); EGFR-tyrosine kinase inhibitor; Non-small cell lung cancer (NSCLC); Afatinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Prevalence of EGFR T790M mutation in NSCLC patients after afatinib failure, and subsequent response to osimertinib
    Hochmair, Maximilian
    Schwab, Sophia
    Burghuber, Otto
    Koger, Renate
    Setinek, Ulrike
    Cseh, Agnieszka
    Fritz, Richard
    Buder, Anna
    Filipits, Martin
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (19-20) : 776 - 776
  • [32] Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib
    Hochmair, M.
    Schwab, S.
    Burghuber, O.
    Koger, R.
    Setinek, U.
    Cseh, A.
    Fritz, R.
    Buder, A.
    Filipits, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2136 - S2136
  • [33] Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting
    Della Gravara, Luigi
    Battiloro, Ciro
    Avellino, Aniello
    Caputo, Francesca
    D'Aniello, Carmine
    Rocco, Danilo
    JOURNAL OF MOLECULAR PATHOLOGY, 2023, 4 (02): : 81 - 88
  • [34] T790M MUTATION IN PATIENTS WITH ACQUIRED RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS: IS IT ASSOCIATED WITH CLINICALLY DISTINCT FEATURES?
    Ji, Jun Ho
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Choi, Yoon-La
    Ahn, Jin Seok
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1073 - S1073
  • [35] The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
    Godin-Heymann, Nadia
    LlIkus, Lindsey
    Brannigan, Brian W.
    McDermott, Ultan
    Lamb, Jennifer
    Maheswaran, Shyamala
    Settleman, Jeffrey
    Haber, Daniel A.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (04) : 874 - 879
  • [36] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
    Li, C.
    Liu, H.
    Zhang, B.
    Zhang, Z.
    Su, Y.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
  • [37] EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
    Chenguang Li
    Rui Jia
    Hailin Liu
    Bin Zhang
    Changli Wang
    Diagnostic Pathology, 13
  • [38] EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
    Li, Chenguang
    Jia, Rui
    Liu, Hailin
    Zhang, Bin
    Wang, Changli
    DIAGNOSTIC PATHOLOGY, 2018, 13
  • [39] Tissue Is the Issue for Diagnosis of EGFR T790M Mutation
    Khan, Jenna
    Pritchard, Colin C.
    Martins, Renato G.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : E91 - E92
  • [40] A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation
    Nakagawa, T.
    Fukuhara, T.
    Imai, K.
    Igusa, R.
    Yokota, H.
    Watanabe, K.
    Suzuki, A.
    Morita, M.
    Inoue, A.
    Miura, M.
    Minamiya, Y.
    Maemondo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S953 - S954
12345